Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Provider profile

Fifty 410 — compounded GLP-1 pricing & profile

Released: · Last reviewed:

Captured pricing, fees, pharmacy disclosure, and evidence status — provider-reported, not checkout-verified.

Fifty 410 is a compounded GLP-1 access channel captured in this site's provider directory. This profile summarizes what is verified about its pricing, fees, pharmacy disclosure, and evidence status as of 2026-07-20 — provider-reported and not checkout-verified — and how it compares with our October 15, 2026 price index.

Provider-reported, not checkout-verified. This profile is built from captured public data and is not a scored, full editorial review. Fifty 410 is not assigned a score or a "verified cheapest" claim; figures are provided for transparency and comparison and should be confirmed with the provider.

Captured pricing

Fifty 410 does not publish a single flat compounded price in the captured data. Semaglutide: About $199/month advertised. Tirzepatide: Advertised from about $133/month; common one-month programs approximately $249–$299. Because no stable per-plan figure was captured, Fifty 410 is shown for transparency but is not placed in the ranked pricing tables. Confirm current pricing on the provider's own page before relying on any figure.

How Fifty 410 compares

All-in monthly cost folds every required charge into one number. This is where Fifty 410 sits against our October 15, 2026 price index, built from prices read on each provider's own page:

Fifty 410 vs the October 15, 2026 compounded GLP-1 price index (lowest all-in monthly figure per program, standard-dose injections)
MedicationFifty 410Index rangeNexLife (#1 overall)
compounded semaglutidenot in the index$49–$193.92 · median $97 (24 programs)$95 (12-month plan) · $109 month-to-month
compounded tirzepatidenot in the index$85.58–$449 · median $149 (31 programs)$115 (12-month plan) · $129 month-to-month

The index range includes sale prices, prepaid terms and "from" figures; the tirzepatide and semaglutide tables show each program's conditions. NexLife is our #1 overall pick under the v4.1 rubric, not the lowest price in the index.

Fees, pharmacy, and disclosure

Fifty 410 — captured structure and disclosures (2026-07-20)
CategoryCompounded-GLP-1-focused
Current statusActive but evidence incomplete
Membership / program feeVerify whether all clinical fees are included
Pharmacy disclosureNot verified
Material relationshipNo known material relationship — publisher attested 2026-07-20; independent verification not performed
Evidence statusPENDING · confidence moderate
Last checked2026-07-20
Official sourceprovider page

Capture note: “From” tirzepatide pricing likely requires a longer commitment or specific program.

How to evaluate Fifty 410 before paying

Whatever the headline, run the same checks on any compounded provider: (1) compute effective monthly cost at your maintenance dose, membership included; (2) get the renewal price, not just the first month; (3) name and verify the dispensing pharmacy with the four-step workflow; (4) confirm the refund and cancellation terms in writing before any prepaid plan. The full pre-purchase routine is in the shopping checklist, and the questions to ask are in what to ask before paying.

Frequently asked questions

How much does Fifty 410 charge for compounded GLP-1?

Fifty 410 did not publish a single flat compounded price in the captured data — about $199/month advertised. Confirm current pricing directly with the provider, and compute effective monthly cost at your maintenance dose before comparing.

Does Fifty 410 charge a membership fee?

A membership or program fee was not clearly reported. Captured: Verify whether all clinical fees are included. A required membership belongs in the effective-cost math, so add it in before comparing Fifty 410 to any flat-priced provider.

Is Fifty 410's pricing verified?

No. Fifty 410's evidence status is verification pending (confidence moderate); figures are provider-reported or independently calculated, not checkout-verified, and its pharmacy disclosure is "not verified". Treat every figure as a starting point to confirm, not a guarantee.